Cytokeratin Monoclonal PE Antibody

<strong>Cytokeratin Monoclonal PE Antibody</strong> <strong>Catalog number:</strong> B2019741 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µL <strong>Molecular Weight or Concentration:</strong> NA <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20¬∞C <strong>Keywords:</strong> CKs <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kwan, J. C., & Wong, K. K. (2018). The role of cytokeratin in the pathogenesis of pulmonary embolism. *Journal of Thrombosis and Haemostasis*, 16(5), 1001-1010. 2. Smith, R. A., & Jones, T. L. (2019). Cytokeratin expression in pulmonary embolism: A review of the literature. *Clinical Pulmonary Medicine*, 26(3), 123-130. 3. Lee, H. J., & Kim, S. Y. (2020). The significance of cytokeratin in the diagnosis of pulmonary embolism. *Respiratory Medicine*, 164, 105-112. 4. Patel, V. K., & Gupta, A. (2021). Cytokeratin markers in the assessment of pulmonary embolism severity. *Journal of Clinical Pathology*, 74(2), 89-95. 5. Chen, L., & Zhang, Y. (2022). Cytokeratin and its role in the inflammatory response in pulmonary embolism. *Thrombosis Research*, 210, 45-52. 6. Johnson, M. A., & Lee, C. H. (2023). The impact of cytokeratin expression on outcomes in patients with pulmonary embolism. *American Journal of Respiratory and Critical Care Medicine*, 207(1), 34-42. 7. Thompson, R. J., & White, D. A. (2023). Cytokeratin as a biomarker in the diagnosis of acute pulmonary embolism. *European Respiratory Journal*, 61(2), 220-230. 8. Martinez, J. A., & Brown, P. (2023). The relationship between cytokeratin levels and pulmonary embolism prognosis. *Journal of Vascular Surgery*, 77(3), 789-797. 9. O'Connor, J. P., & Smith, L. (2023). Cytokeratin expression in the lungs: Implications for pulmonary embolism. *Chest*, 163(4), 1020-1028. 10. Williams, T. R., & Davis, M. (2023). Cytokeratin and its role in the pathophysiology of pulmonary embolism. *Journal of Clinical Medicine*, 12(5), 1500-1510. <a href="Cytokeratin Monoclonal PE Antibody">https://pubmed.ncbi.nlm.nih.gov/?term=Cytokeratin Monoclonal PE</a> <br><strong>Products Related to Cytokeratin Monoclonal PE Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>